Announcement • May 19
Eurobio Scientific Société anonyme, Annual General Meeting, Jun 18, 2026 Eurobio Scientific Société anonyme, Annual General Meeting, Jun 18, 2026. Location: 7 avenue de scandinavie, les ulis France Announcement • Apr 17
Eurobio Scientific Société anonyme (ENXTPA:ALERS) entered into a definitive agreement to acquire Caredx AB and Kitted Laboratory Products Business and Related Software of CareDx, Inc. (NasdaqGM:CDNA) for $170 million. Eurobio Scientific Société anonyme (ENXTPA:ALERS) entered into a definitive agreement to acquire Caredx AB and Kitted Laboratory Products Business and Related Software of CareDx, Inc. (NasdaqGM:CDNA) for $170 million on April 15, 2026. A cash consideration of $170 million, subject to customary adjustments, will be paid by Eurobio Scientific Société anonyme. Following closing, the LabProducts division will be integrated into GenDx’s operations, with a focus on maintaining continuity for customers, partners, and employees.
The transaction is subject to, among others, Swedish regulatory review, execution of transitional services agreement, and execution of distribution agreement. The deal has been approved by the boards of directors of CareDx and EuroBio Scientific. The transaction is expected to be completed by the end of CareDx’s third quarter in 2026.
William P. Kahn of Kahn Partners LLP acted as legal advisor and Cowen Inc. acted as financial advisor for Eurobio Scientific Société anonyme. Douglas N. Cogen and Lynda Twomey of Fenwick & West LLP acted as legal advisor and Rothschild & Co US Inc. acted as financial advisor for CareDx, Inc. Reported Earnings • Apr 12
Full year 2025 earnings released Full year 2025 results: Revenue: €169.0m (up 9.1% from FY 2024). Net income: €4.90m (up 23% from FY 2024). Profit margin: 2.9% (up from 2.6% in FY 2024). The increase in margin was driven by higher revenue. Announcement • Jan 29
Eurobio Scientific Société anonyme to Report Fiscal Year 2025 Results on Apr 10, 2026 Eurobio Scientific Société anonyme announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Apr 10, 2026 Board Change • Jan 24
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Patrick de Roquemaurel was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Major Estimate Revision • Oct 01
Consensus revenue estimates increase by 11%, EPS downgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from €151.1m to €168.4m. EPS estimate fell from €1.16 to €0.78. Net income forecast to grow 308% next year vs 23% growth forecast for Biotechs industry in France. Consensus price target of €30.00 unchanged from last update. Share price fell 2.2% to €24.90 over the past week. Reported Earnings • Sep 26
First half 2025 earnings released First half 2025 results: Revenue: €81.2m (up 11% from 1H 2024). Net income: €2.40m (down 40% from 1H 2024). Profit margin: 3.0% (down from 5.4% in 1H 2024). Revenue is forecast to grow 5.1% p.a. on average during the next 2 years, compared to a 23% growth forecast for the Biotechs industry in France. Announcement • Jul 02
Eurobio Scientific Société anonyme (ENXTPA:ALERS) completed the acquisition of Assets of the Life Science Unit from Voden Medical Instruments SpA. Eurobio Scientific Société anonyme (ENXTPA:ALERS) agreed to acquire Assets of the Life Science Unit from Voden Medical Instruments SpA on March 11, 2025. Payment will be made entirely in cash, financed with both the Group's cash and through a bank loan. The expected completion of the transaction is July 1, 2025.
Eurobio Scientific Société anonyme (ENXTPA:ALERS) completed the acquisition of Assets of the Life Science Unit from Voden Medical Instruments SpA on July 1, 2025. Announcement • May 13
Eurobio Scientific Société anonyme, Annual General Meeting, Jun 19, 2025 Eurobio Scientific Société anonyme, Annual General Meeting, Jun 19, 2025. Location: 7 avenue de scandinavie, les ulis France New Risk • Apr 29
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.6% Last year net profit margin: 3.7% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company. Reported Earnings • Apr 29
Full year 2024 earnings released Full year 2024 results: Revenue: €154.9m (up 19% from FY 2023). Net income: €4.00m (down 17% from FY 2023). Profit margin: 2.6% (down from 3.7% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.1% p.a. on average during the next 2 years, compared to a 26% growth forecast for the Biotechs industry in France. New Risk • Apr 13
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company. Announcement • Mar 13
Eurobio Scientific Société anonyme (ENXTPA:ALERS) agreed to acquire Assets of the Life Science Unit from Voden Medical Instruments SpA. Eurobio Scientific Société anonyme (ENXTPA:ALERS) agreed to acquire Assets of the Life Science Unit from Voden Medical Instruments SpA on March 11, 2025. Payment will be made entirely in cash, financed with both the Group's cash and through a bank loan.
The expected completion of the transaction is July 1, 2025. New Risk • Dec 12
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €3.4m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. This is currently the only risk that has been identified for the company. Announcement • Oct 30
Diaxonhit ORD to Be Deleted from OTC Equity Diaxonhit ORD (France) will be deleted from OTC Equity effective October 29, 2024, due to Inactive Security. Reported Earnings • Sep 29
First half 2024 earnings released: EPS: €0.40 (vs €0.21 in 1H 2023) First half 2024 results: EPS: €0.40 (up from €0.21 in 1H 2023). Revenue: €73.5m (up 24% from 1H 2023). Net income: €4.00m (up 83% from 1H 2023). Profit margin: 5.4% (up from 3.7% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 32% growth forecast for the Biotechs industry in France. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance. Announcement • Aug 02
NextStage AM, IK Partners, Denis Fortier, Cathie Marsais, Olivier Bosc, JeanMichel Carle-Grandmougin and Hervé Duchesne de Lamotte proposed to acquire remaining 65.96% stake in Eurobio Scientific Société anonyme (ENXTPA:ALERS) from Wietse Mulder and others for approximately €170 million. NextStage AM, IK Partners, Denis Fortier, Cathie Marsais, Olivier Bosc, JeanMichel Carle-Grandmougin and Hervé Duchesne de Lamotte proposed to acquire remaining 65.96% stake in Eurobio Scientific Société anonyme (ENXTPA:ALERS) from Wietse Mulder and others for approximately €170 million on July 31, 2024. The Offer will be made at a price of €25.30 per Eurobio Scientific share. Under the terms of the Investment Agreement, the Bidder and the members of the Consortium declared that they were acting in concert within the meaning of article L. 233-10 of the French Commercial Code and EurobioNext, a shareholder and director of the Company, has undertaken to contribute to the Bidder all of the shares of the Company that it holds (i.e. 34.04% of the share capital and theoretical voting rights of the Company, by way of a contribution in kind with effect before the first settlement-delivery of the Offer if the Offer is successful. Echiumbio Holding B.V., the holding company of Wietse Mulder, holding 9.42% of the Company's share capital to date, committed to IK Partners to tender the Company shares it holds to the Offer. Subject to the issue by the AMF of its opinion on the conformity of the Offer, the Offer will be opened in the days following the Bidder's obtaining the necessary authorizations for the control of foreign investments in France. In addition to the mandatory expiry threshold provided, the Offer will be subject to a waiver threshold pursuant to Article 231-9, II of the AMF's General Regulation, allowing the Bidder to withdraw the Offer if less than 66.66% of the Company's shares and theoretical voting rights are tendered at the end of the Offer. The Offer is subject to the condition precedent of the authorization from the European Commission under merger control regulations, it being specified that the Bidder reserves the right to waive this condition, and the opening of the Offer is subject to the prior authorization from the competent foreign investments control authorities in France and Italy. Valuation Update With 7 Day Price Move • Aug 01
Investor sentiment improves as stock rises 45% After last week's 45% share price gain to €24.55, the stock trades at a forward P/E ratio of 26x. Average trailing P/E is 33x in the Biotechs industry in Europe. Total returns to shareholders of 44% over the past three years. Valuation Update With 7 Day Price Move • Jul 15
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €16.32, the stock trades at a forward P/E ratio of 17x. Average trailing P/E is 29x in the Biotechs industry in Europe. Total loss to shareholders of 12% over the past three years. Reported Earnings • Apr 13
Full year 2023 earnings released Full year 2023 results: Revenue: €130.6m (down 15% from FY 2022). Net income: €4.80m (down 81% from FY 2022). Profit margin: 3.7% (down from 16% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 6.4% p.a. on average during the next 2 years, compared to a 34% growth forecast for the Biotechs industry in France. Price Target Changed • Apr 12
Price target increased by 7.1% to €30.00 Up from €28.00, the current price target is provided by 1 analyst. New target price is 89% above last closing price of €15.84. Stock is down 3.4% over the past year. The company is forecast to post earnings per share of €0.43 for next year compared to €2.44 last year. Announcement • Apr 11
Eurobio Scientific Société anonyme, Annual General Meeting, Jun 13, 2024 Eurobio Scientific Société anonyme, Annual General Meeting, Jun 13, 2024. Announcement • Jan 31
Eurobio Scientific Société anonyme to Report Fiscal Year 2023 Results on Apr 10, 2024 Eurobio Scientific Société anonyme announced that they will report fiscal year 2023 results at 5:40 PM, Central European Standard Time on Apr 10, 2024 Price Target Changed • Jan 31
Price target increased by 7.4% to €29.00 Up from €27.00, the current price target is provided by 1 analyst. New target price is 84% above last closing price of €15.74. Stock is down 11% over the past year. The company is forecast to post earnings per share of €0.90 for next year compared to €2.44 last year. Announcement • Jan 31
Eurobio Scientific Société anonyme (ENXTPA:ALERS) acquired Alpha Biotech Ltd. Eurobio Scientific Société anonyme (ENXTPA:ALERS) acquired Alpha Biotech Ltd on January 3, 2024.Eurobio Scientific Société anonyme (ENXTPA:ALERS) completed the acquisition of Alpha Biotech Ltd on January 3, 2024. Announcement • Nov 09
Eurobio Scientific Appoints Catherine Courboillet to the Board of Directors Eurobio Scientific announced Ms Catherine Courboillet has agreed to join the Board of Directors. A resolution relating to her appointment will be included on the agenda of the next general shareholder meeting in June 2024. Catherine Courboillet's appointment is part of the Board strategy to broaden the profiles and skills of its members in the field of medical diagnostics. She will bring her expertise in customer experience and her extensive knowledge of key market players. Ms. Catherine Courboillet began her career at Pharmacia DIAG, where she quickly held several management positions including sales and marketing. She then developed the specialized biology laboratory of Générale de Santé before joining Cerba in 1999, which became the Cerba Healthcare Group under her leadership. She has 30 years of experience in the field of life sciences and medical diagnostics. She has developed, over the years, unique skills in business management and has carried out numerous external growth projects in the field of medical diagnostics in France, Europe and internationally. Valuation Update With 7 Day Price Move • Oct 25
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €16.00, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 26x in the Biotechs industry in Europe. Total loss to shareholders of 2.1% over the past three years. Major Estimate Revision • Oct 18
Consensus EPS estimates increase by 30% The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate increased from €0.63 to €0.82. Revenue forecast unchanged at €123.2m. Net income forecast to grow 21% next year vs 15% growth forecast for Biotechs industry in France. Consensus price target down from €28.00 to €27.00. Share price rose 6.5% to €13.84 over the past week. Reported Earnings • Oct 12
First half 2023 earnings released First half 2023 results: Revenue: €59.4m (down 30% from 1H 2022). Net income: €2.20m (down 89% from 1H 2022). Profit margin: 3.7% (down from 23% in 1H 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in France. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Buying Opportunity • Oct 02
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 1.7%. The fair value is estimated to be €17.73, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 17%. For the next 3 years, revenue is forecast to grow by 0.9% per annum. Earnings is forecast to decline by 23% per annum over the same time period. Price Target Changed • Jul 11
Price target increased by 7.7% to €28.00 Up from €26.00, the current price target is provided by 1 analyst. New target price is 87% above last closing price of €15.00. Stock is down 28% over the past year. The company is forecast to post earnings per share of €0.63 for next year compared to €2.44 last year. Reported Earnings • Apr 06
Full year 2022 earnings released Full year 2022 results: Revenue: €152.9m (down 18% from FY 2021). Net income: €24.9m (down 59% from FY 2021). Profit margin: 16% (down from 33% in FY 2021). The decrease in margin was primarily driven by lower revenue. Revenue is expected to decline by 1.6% p.a. on average during the next 3 years, while revenues in the Biotechs industry in France are expected to grow by 18%. Announcement • Feb 09
Eurobio Scientific Société anonyme to Report First Half, 2023 Results on Oct 11, 2023 Eurobio Scientific Société anonyme announced that they will report first half, 2023 results on Oct 11, 2023 Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Independent Director Patrick de Roquemaurel was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 16
First half 2022 earnings released First half 2022 results: Revenue: €84.3m (down 12% from 1H 2021). Net income: €19.2m (down 42% from 1H 2021). Profit margin: 23% (down from 35% in 1H 2021). The decrease in margin was primarily driven by lower revenue. Revenue is expected to decline by 10.0% p.a. on average during the next 3 years, while revenues in the Biotechs industry in France are expected to grow by 30%. Valuation Update With 7 Day Price Move • Oct 06
Investor sentiment improved over the past week After last week's 15% share price gain to €17.84, the stock trades at a trailing P/E ratio of 3.2x. Average forward P/E is 27x in the Biotechs industry in Europe. Total returns to shareholders of 381% over the past three years. Price Target Changed • Oct 04
Price target decreased to €32.00 Down from €35.00, the current price target is provided by 1 analyst. New target price is 94% above last closing price of €16.50. Stock is down 6.0% over the past year. The company is forecast to post earnings per share of €2.56 for next year compared to €5.58 last year. Buying Opportunity • Sep 16
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 2.3%. The fair value is estimated to be €22.64, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 54% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to decline by 15% per annum. Earnings is also forecast to decline by 54% per annum over the same time period. Buying Opportunity • Sep 01
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 15%. The fair value is estimated to be €22.52, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 54% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to decline by 15% per annum. Earnings is also forecast to decline by 54% per annum over the same time period. Price Target Changed • Jul 28
Price target decreased to €35.00 Down from €39.00, the current price target is provided by 1 analyst. New target price is 81% above last closing price of €19.33. Stock is up 11% over the past year. The company is forecast to post earnings per share of €2.56 for next year compared to €5.58 last year. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Apr 13
Investor sentiment deteriorated over the past week After last week's 18% share price decline to €17.50, the stock trades at a trailing P/E ratio of 3.1x. Average forward P/E is 38x in the Biotechs industry in Europe. Total returns to shareholders of 430% over the past three years. Reported Earnings • Apr 08
Full year 2021 earnings released Full year 2021 results: Revenue: €185.3m (down 2.1% from FY 2020). Net income: €60.5m (down 18% from FY 2020). Profit margin: 33% (down from 39% in FY 2020). The decrease in margin was primarily driven by higher expenses. Over the next year, revenue is expected to shrink by 30% compared to a 276% growth forecast for the pharmaceuticals industry in France. Valuation Update With 7 Day Price Move • Dec 22
Investor sentiment improved over the past week After last week's 18% share price gain to €25.82, the stock trades at a trailing P/E ratio of 3.5x. Average forward P/E is 27x in the Biotechs industry in Europe. Total returns to shareholders of 777% over the past three years. Reported Earnings • Oct 14
First half 2021 earnings released The company reported a solid first half result with improved earnings and revenues, although profit margins were weaker. First half 2021 results: Revenue: €95.9m (up 54% from 1H 2020). Net income: €33.1m (up 29% from 1H 2020). Profit margin: 35% (down from 41% in 1H 2020). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Jul 08
Investor sentiment improved over the past week After last week's 16% share price gain to €20.72, the stock trades at a trailing P/E ratio of 3.2x. Average forward P/E is 24x in the Biotechs industry in Europe. Total returns to shareholders of 274% over the past three years. Reported Earnings • May 01
Full year 2020 earnings released The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €189.2m (up 218% from FY 2019). Net income: €73.5m (up €70.3m from FY 2019). Profit margin: 39% (up from 5.3% in FY 2019). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Jan 19
Investor sentiment improved over the past week After last week's 16% share price gain to €22.30, the stock is trading at a trailing P/E ratio of 8.9x, up from the previous P/E ratio of 7.6x. This compares to an average P/E of 19x in the Biotechs industry in France. Total returns to shareholders over the past three years are 381%. Valuation Update With 7 Day Price Move • Jan 14
Investor sentiment improved over the past week After last week's 16% share price gain to €19.40, the stock is trading at a trailing P/E ratio of 7.7x, up from the previous P/E ratio of 6.6x. This compares to an average P/E of 16x in the Biotechs industry in France. Total returns to shareholders over the past three years are 308%. Is New 90 Day High Low • Jan 11
New 90-day high: €18.35 The company is up 25% from its price of €14.65 on 13 October 2020. The French market is up 14% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Biotechs industry, which is also up 25% over the same period. Valuation Update With 7 Day Price Move • Dec 03
Market bids up stock over the past week After last week's 16% share price gain to €15.65, the stock is trading at a trailing P/E ratio of 6.2x, up from the previous P/E ratio of 5.3x. This compares to an average P/E of 44x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 246%. Valuation Update With 7 Day Price Move • Dec 01
Market bids up stock over the past week After last week's 19% share price gain to €15.55, the stock is trading at a trailing P/E ratio of 6.2x, up from the previous P/E ratio of 5.2x. This compares to an average P/E of 44x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 246%. Valuation Update With 7 Day Price Move • Nov 13
Market pulls back on stock over the past week After last week's 15% share price decline to €15.10, the stock is trading at a trailing P/E ratio of 6x, down from the previous P/E ratio of 7.1x. This compares to an average P/E of 42x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 228%. Is New 90 Day High Low • Oct 26
New 90-day high: €17.10 The company is up 45% from its price of €11.80 on 28 July 2020. The French market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 15% over the same period. Is New 90 Day High Low • Oct 05
New 90-day high: €13.90 The company is up 65% from its price of €8.40 on 07 July 2020. The French market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 7.0% over the same period. 
